Nurtec™ ODT (rimegepant) 75 mg Orally Disintegrating Tablets

Long-term safety maintained through 52 weeks¹

<2.7% (n=48/1798) of patients receiving rimegepant discontinued due to AEs³

1798 subjects were exposed to >111,000 doses of rimegepant⁴

Can be used to treat up to 15 migraines per month¹

A long-term open-label safety study evaluated rimegepant 75 mg in patients (N=1798) exposed to multiple doses, as needed up to one dose per day, for up to 52 weeks.^1,5

Long-term Safety Study Design

Long-term safety of rimegepant is supported by an open‑label trial^1,5

Enrollment Groups

History of Moderate to Severe Migraine

2-8 attacks/month (N=1089)

9-14 attacks/month (N=511)

4-14 attacks/month (N=308)

Rimegepant Treatment

Up to 52 weeks as needed up to 1x/daily dosing
(n=1512)

Up to 12 weeks fixed dosing EOD + PRN dosing
(n=286)

110 of the patients enrolled were not treated⁵

PRN: as needed; EOD: every other day⁵

Average of 7.7 doses per 4 weeks/patient for up to 52 weeks (n=1798)⁵
≥8 doses per 4 weeks for ≥24 weeks (n=368)⁵
≥13 doses per 4 weeks for at least 12 weeks (n=306)⁵

References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. 3. Data on File. RIM121. Biohaven Pharmaceuticals Inc. 4. Data on File. RIM113. Biohaven Pharmaceuticals Inc. 5. Data on File. RIM131. Biohaven Pharmaceuticals Inc.

Terms & Conditions

To the Patient: In order to participate in the Nurtec ODT Patient Savings Program ("Program"), you must have a valid prescription for Nurtec™ ODT (rimegepant) orally disintegrating tablets, meet the eligibility requirements set forth herein, adhere to the terms and conditions stated in the Restrictions section below, and present this card to your pharmacist. Eligible patients with commercial insurance may pay as little as $0 out of pocket and limited to one 8‑tablet prescription per month. Patients with questions about the Program should call 1‑800‑761‑1568.

To the Pharmacist: By redeeming this offer, the Pharmacist certifies: (a) that the Pharmacy has not submitted, and will not submit, a claim for reimbursement under any federal, state, or other government programs for this prescription or where prohibited by law and (b) the Pharmacist will adhere to the terms and conditions stated in the Restrictions section below.

Pharmacist Instructions: For Commercially Insured Patients, please submit this claim to the patient's primary Third‑Party Payer first, then submit the balance due to CHANGE HEALTHCARE as a Secondary Payer COB (coordination of benefits) with patient responsibility and a valid Other Coverage Code (e.g. 08). Reimbursement will be received from CHANGE HEALTHCARE. For questions, please call the Concierge line for Nurtec ODT at 1‑800‑731‑4997, Monday – Friday, 8 am – 8 pm ET.

Restrictions: This offer is not valid for Non‑Insured/Cash-Paying Patients. This Program is not valid for prescriptions covered by or submitted for reimbursement in part or in full by any state or federally funded programs, including but not limited to Medicare, Medicaid, Medigap, VA, TRICARE (DOD). Patients with managed care restrictions (e.g., prior authorization, step edit) may not be eligible for this offer if such managed care restrictions persist. Continued eligibility may require that the patient has a prior authorization form submitted. This offer may not be used with any other financial assistance program, free trial, discount, prescription savings card or other offer. Valid only for patients 18 years and older in the United States including the Commonwealth of Puerto Rico. This Program is void if copied, transferred, purchased, altered, or traded and where prohibited by law. Limit one offer per individual. This offer expires on December 31, 2021. Biohaven Pharmaceuticals reserves the right to rescind, revoke or amend this offer without notice anytime. This Program is managed by ConnectiveRx on behalf of Biohaven Pharmaceuticals.

Safety

Most Common AE¹

Long-term safety maintained through 52 weeks¹

< Previous Page

Next Page >

Important Safety Information

Indication

Safety

Most Common AE1

Long-term safety maintained through 52 weeks1

< Previous Page

Next Page >

Important Safety Information

Indication

Most Common AE¹

Long-term safety maintained through 52 weeks¹